FDA Recalls Finder

FDA approves Eylea for eye disorder in older people
18 November 2011, 4:52 pm

The U.S. Food and Drug Administration today approved Eylea (aflibercept) to treat patients with wet (neovascular) age-related macular degeneration (AMD), a leading cause of vision loss and blindness in Americans ages 60 and older. AMD gradually destroys a person’s sharp, central vision.

Source: Food and Drug Administration--Press Releases